First Wave BioPharma (AzurRX Biopharma) ^{Priced, Nasdaq: FWBI}

We are engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Non-systemic biologics are non-absorbable drugs that act locally without reaching the systemic circulation, i.e. the intestinal lumen, skin or mucosa.  Our current product pipeline consists of two therapeutic proteins under development. MS1819 - an autologous (from the same organism) yeast recombinant lipase for exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis. A recombinant lipase is an enzyme that breaks up fat molecules, which is created from new combinations of genetic material in yeast. AZX1101 - a recombinant ß-lactamase combination of bacterial origin for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of ß-lactam antibiotics, as well as prevention of antibiotic-associated diarrhea. A recombinant ß-lactamase is an enzyme that breaks up molecules with a beta-lactam ring as is often seen in antibiotics, which is created from new combinations of genetic material in yeast.